Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s68770
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Humoral Immune Responses Toward Tumor-Derived Antigens in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Oncotarget
Oncology
2016English

Real World Outcomes of Obinutuzumab Monotherapy in Patients With Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Chemoimmunotherapy May Overcome the Adverse Prognostic Significance of 11q Deletion in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Cancer
Cancer ResearchOncology
2008English

Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Externally Validated Predictive Clinical Model for Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

American Journal of Hematology
Hematology
2015English

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
2014English

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Treatment of Patients With Chronic Lymphocytic Leukemia With 17p Deletion: The Saga Continues

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy